🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT05876533
Active, not recruiting Observational

R&D Study to Evaluate Cordio's Usability and to Collect Patient Speech Utterances

NCT05876533 · tracked via the Priya Life Science USA tracker
Sponsor
Cordio Medical
Phase
Observational
Started
2022-03-18
Last updated
2024-12-31

Condition(s) studied

Chronic Heart Failure

Investigational drug(s) / intervention(s)

Cordio HearO

Cordio HearO: Cordio HearO is a software medical device that remotely monitors Congestive Heart Failure (CHF) patients by detecting changes in the patients' recorded voice relative to a baseline. The system is comprised of a mobile application (or "app") that is deployed on a mobile platform, and a web-based portal that enables caregivers to manage their patients

Study summary

To determine the usability and technical aspects of Cordio HearO™

Eligibility

Sex
ALL
Min age
22 Years
Max age
Healthy volunteers
No
Major inclusion Criteria: 1. Adults patients 2. Diagnosed with Symptomatic Chronic Heart Failure \[NYHA II-IVa (ambulatory)\] 3. At least one of the following: 1. One ADHF hospitalization in the last 12 months 2. One unplanned IV/SC diuretic administration in the last 6 months 3. Two unplanned IV/SC diuretic administration in the last 12 months 4. NTProBNP \>500 pg/ml or BNP\*\> 150 pg/ml at screening visit 4. Clinically stable HF 5. Willing to participate as evidenced by signing the written informed consent. 6. Male or non-pregnant female patient (pre-menopausal women will confirm verbally). Major exclusion Criteria: 1. Not able to read in Hebrew, Russian, Arabic, English and/or Spanish. 2. Unable to comply with daily use of the App 3. Major cardiovascular event 4. Had a Cardiac Resynchronization Device (CRT) implanted or upgrading ≤ 1 month prior to screening visit. 5. Has estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73 meter square (Cockroft-Gault formula). 6. Is likely to undergo heart transplantation/ LVAD within 6 months of Screening Visit.

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Kurker Family Medicine South Windsor Connecticut
C&R Research Services Cape Coral Florida
C&R Research Services Miami Florida
C&R Research Services Miami Florida
Lake County Med Grp Athens Georgia
Barzilai Medical Center- Cardiology Ashkelon Israel
Heart Failure Clinic - Clallit Be'er Sheva Beersheba Israel
Rabin Medical Center - Cardiology- CHF Petah Tikva Israel

More Cordio Medical trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05876533 on ClinicalTrials.gov ↗ ← All trials in the USA